|
35 Companies |
|
34 Products |
|
34 Products |
|
43 Mechanisms of Action |
|
0 Trials |
|
224 News |
|
| «12345» |
- Biomarker, Enrollment open, HEOR: Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients (clinicaltrials.gov) - Aug 22, 2013
P2, N=20, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting
- | avasopasem manganese (GC4419) / Galera Therap
New P1 trial, Combination therapy: A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck (clinicaltrials.gov) - Aug 11, 2013
P1, N=30, Recruiting, Sponsor: Galera Therapeutics, Inc.
- | New P2 trial: ROSAM: Role of SAMITAL (clinicaltrials.gov) - Aug 7, 2013
P2, N=120, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
- || New P3 trial: RadioHum: Radiotherapy With Humidification in Head And Neck Cancer (clinicaltrials.gov) - Aug 5, 2013
P3, N=210, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
- | Enrollment closed: RadioHum: Radiotherapy With Humidification in Head And Neck Cancer (clinicaltrials.gov) - Aug 4, 2013
P3, N=210, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- Enrollment change, Adverse events: Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area (clinicaltrials.gov) - Jul 28, 2013
P=N/A, N=58, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Not yet recruiting --> Active, not recruiting N=30 --> 58
- Enrollment open: Herbal Mouthrinse for Oral Mucositis Study (clinicaltrials.gov) - Jul 28, 2013
P2, N=50, Recruiting, Sponsor: Medical University of South Carolina
N=30 --> 58 Not yet recruiting --> Recruiting
- |||||||||| riviciclib (P27600) / Piramal Phytocare
New P2/3 trial, Metastases: A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00 (clinicaltrials.gov) - Jul 17, 2013
P2/3, N=73, Active, not recruiting, Sponsor: Piramal Enterprises Limited
- Trial completion: SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (clinicaltrials.gov) - Jul 14, 2013
P=N/A, N=181, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Herbal Mouthrinse for Oral Mucositis Study (clinicaltrials.gov) - Jul 10, 2013
P2, N=50, Recruiting, Sponsor: Medical University of South Carolina
- Enrollment change: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=180 --> 0
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change, Surgery, Metastases: Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 25, 2013
P3, N=21, Completed, Sponsor: Radiation Therapy Oncology Group
N=180 --> 0 N=298 --> 21
- Trial initiation date: Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis (clinicaltrials.gov) - Jun 24, 2013
P3, N=18, Completed, Sponsor: Insys Therapeutics Inc
N=298 --> 21 Initiation date: Jun 2009 --> Oct 2009
- TXA-127 / Constant Therap
New P2 trial: Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Jun 18, 2013
P2, N=0, Withdrawn, Sponsor: US Biotest, Inc.
- TXA-127 / Constant Therap
New P2 trial: Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation (clinicaltrials.gov) - Jun 18, 2013
P2, N=0, Withdrawn, Sponsor: US Biotest, Inc.
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment change, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Jun 13, 2013
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Jun 2009 --> Oct 2009 N=80 --> 18
- | Torisel (temsirolimus) / Pfizer
Trial initiation date, Stroma: COMTT: Caphosol in Oral Mucositis Due to Targeted Therapy (clinicaltrials.gov) - Jun 10, 2013
P3, N=60, Recruiting, Sponsor: Christine B Boers-Doets
N=80 --> 18 Initiation date: Feb 2011 --> Sep 2011
- | Torisel (temsirolimus) / Pfizer
Enrollment open, Stroma: COMTT: Caphosol in Oral Mucositis Due to Targeted Therapy (clinicaltrials.gov) - Jun 10, 2013
P3, N=60, Recruiting, Sponsor: Christine B Boers-Doets
Initiation date: Feb 2011 --> Sep 2011 Not yet recruiting --> Recruiting
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) - May 29, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=200 --> 0
- Trial withdrawal: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (clinicaltrials.gov) - May 13, 2013
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
N=200 --> 0 Not yet recruiting --> Withdrawn
- Enrollment change: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (clinicaltrials.gov) - May 13, 2013
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Withdrawn N=90 --> 0
- | Enrollment open: A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - May 2, 2013
P3, N=108, Recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
N=90 --> 0 Not yet recruiting --> Recruiting
- ||| Enrollment open: Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer (clinicaltrials.gov) - Apr 22, 2013
P=N/A, N=105, Recruiting, Sponsor: Organ, Tissue, Regeneration, Repair and Replacement
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial completion, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Apr 22, 2013
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- morphine sulphate / Generic mfg.
New P2/3 trial: Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer (clinicaltrials.gov) - Apr 21, 2013
P2/3, N=30, Completed, Sponsor: Isfahan University of Medical Sciences
- || Trial initiation date: A Comparative Investigation of Standard Of Care (SOC) and Episil (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=116, Completed, Sponsor: Camurus AB
Active, not recruiting --> Completed Initiation date: Nov 2012 --> Feb 2013
- melphalan / Generic mfg.
Trial termination, Adverse events: Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=95, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Initiation date: Nov 2012 --> Feb 2013 Completed --> Terminated; The original PI on this study left VICC, thus study was closed.
- melphalan / Generic mfg.
Enrollment change, Adverse events: Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=95, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Completed --> Terminated; The original PI on this study left VICC, thus study was closed. N=432 --> 95
- Trial initiation date: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (clinicaltrials.gov) - Feb 24, 2013
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
N=432 --> 95 Initiation date: Aug 2012 --> May 2013
- || New P3 trial: A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Feb 21, 2013
P3, N=108, Recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
- Enrollment change: A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Feb 18, 2013
P2, N=31, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
Initiation date: Aug 2012 --> May 2013 N=20 --> 31
- Trial completion: A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Feb 18, 2013
P2, N=31, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
N=20 --> 31 Recruiting --> Completed
- |||||| doxepin / Generic mfg.
Enrollment open: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Jan 15, 2013
P3, N=198, Recruiting, Sponsor: North Central Cancer Treatment Group
Recruiting --> Completed Completed --> Recruiting
- Trial completion: Use of Chamomilla Recutita in Mucositis (clinicaltrials.gov) - Jan 10, 2013
P2, N=40, Completed, Sponsor: University of Sao Paulo
Completed --> Recruiting Recruiting --> Completed
- | dapatifagene navolactibac (AG013) / Oragenics
Trial completion: Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck (clinicaltrials.gov) - Dec 5, 2012
P1, N=25, Completed, Sponsor: ActoGeniX N.V.
Recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy (clinicaltrials.gov) - Nov 27, 2012
P2, N=30, Completed, Sponsor: Azad University of Medical Sciences
- Trial completion: L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=10, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial termination: A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain (clinicaltrials.gov) - Nov 21, 2012
P1/2, N=60, Terminated, Sponsor: Mundipharma Research Limited
Active, not recruiting --> Completed Recruiting --> Terminated; 25 patients have been recruited and it was considered that further recruitment would add no extra PK information
- New P1/2 trial: Effect of Quercetin in Prevention and Treatment of Oral Mucositis (clinicaltrials.gov) - Nov 20, 2012
P1/2, N=20, Completed, Sponsor: Mashhad University of Medical Sciences
- entolimod (STAT-600) / Coeptis
New P1 trial, Metastases: Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Nov 15, 2012
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
- Enrollment change: Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=70, Completed, Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Recruiting --> Terminated; 25 patients have been recruited and it was considered that further recruitment would add no extra PK information N=25 --> 70
- Trial completion: Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy (clinicaltrials.gov) - Nov 7, 2012
P=N/A, N=70, Completed, Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
N=25 --> 70 Enrolling by invitation --> Completed
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
New P2 trial, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Sep 6, 2012
P2, N=18, Completed, Sponsor: Roswell Park Cancer Institute
- Trial withdrawal: Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Enrolling by invitation --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=50 --> 0
- New P2 trial: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy (clinicaltrials.gov) - Aug 26, 2012
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
- New P2 trial: Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer (clinicaltrials.gov) - Jul 29, 2012
P2, N=10, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- | melphalan / Generic mfg.
New P2 trial: Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients (clinicaltrials.gov) - Jul 26, 2012
P2, N=140, Recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
- || Kepivance (palifermin) / SOBI, Amgen
Trial completion: Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) (clinicaltrials.gov) - Jul 12, 2012
P3, N=47, Completed, Sponsor: Swedish Orphan Biovitrum
N=50 --> 0 Active, not recruiting --> Completed
- ||||| Kepivance (palifermin) / SOBI, Amgen
Trial initiation date, Metastases: Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 11, 2012
P3, N=188, Active, not recruiting, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Initiation date: Jan 2005 --> Aug 2005